Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$776.18
-2.4%
$780.19
$677.09
$972.53
$735.61B0.413.67 million shs4.11 million shs
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
$68.50
+1.2%
$69.11
$57.00
$145.99
$305.85B0.667.21 million shs5.62 million shs
Vivani Medical, Inc. stock logo
VANI
Vivani Medical
$1.32
+0.8%
$1.12
$0.91
$11.40
$78.20M2.93100,277 shs124,810 shs
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
$26.52
-5.9%
$27.19
$18.92
$81.73
$2.98B0.654.01 million shs6.32 million shs
 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
0.00%+1.67%+5.13%-5.97%-14.27%
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
0.00%-7.13%-4.06%-1.55%-52.01%
Vivani Medical, Inc. stock logo
VANI
Vivani Medical
0.00%+4.76%+6.43%+25.71%+4.76%
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
0.00%+1.96%-1.70%+9.81%-49.97%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
4.9852 of 5 stars
4.44.03.34.02.81.71.9
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
4.6694 of 5 stars
4.15.02.50.02.40.03.1
Vivani Medical, Inc. stock logo
VANI
Vivani Medical
3.3402 of 5 stars
3.55.00.00.02.23.30.0
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
4.3687 of 5 stars
4.51.00.04.71.43.30.0
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
2.75
Moderate Buy$1,011.6130.33% Upside
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
2.27
Hold$112.0063.50% Upside
Vivani Medical, Inc. stock logo
VANI
Vivani Medical
3.00
Buy$4.00203.03% Upside
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
3.00
Buy$87.15228.63% Upside

Current Analyst Ratings Breakdown

Latest VANI, NVO, LLY, and VKTX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/25/2025
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$102.00
6/20/2025
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$936.00
6/5/2025
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Erste Group Bank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeBuy ➝ Hold
5/23/2025
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy
5/19/2025
Vivani Medical, Inc. stock logo
VANI
Vivani Medical
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$4.00 ➝ $4.00
5/2/2025
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$1,100.00 ➝ $1,050.00
5/1/2025
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight
5/1/2025
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight
5/1/2025
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy
4/29/2025
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
4/28/2025
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
HSBC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeBuy ➝ Reduce$1,150.00 ➝ $700.00
(Data available from 6/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$45.04B16.33$14.25 per share54.48$15.03 per share51.64
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
$42.12B7.26$3.90 per share17.56$4.66 per share14.70
Vivani Medical, Inc. stock logo
VANI
Vivani Medical
N/AN/AN/AN/A$0.30 per shareN/A
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
N/AN/AN/AN/A$7.90 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$10.59B$12.2963.1624.941.1322.67%85.51%15.74%8/7/2025 (Estimated)
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
$14.64B$3.3820.2714.701.2234.52%80.94%24.23%8/6/2025 (Estimated)
Vivani Medical, Inc. stock logo
VANI
Vivani Medical
-$23.49M-$0.43N/AN/AN/AN/A-133.07%-56.50%8/12/2025 (Estimated)
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
-$109.96M-$1.15N/AN/AN/AN/A-14.41%-14.02%7/23/2025 (Estimated)

Latest VANI, NVO, LLY, and VKTX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
7/23/2025Q2 2025
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
-$0.44N/AN/AN/AN/AN/A
5/13/2025Q1 2025
Vivani Medical, Inc. stock logo
VANI
Vivani Medical
-$0.10-$0.11-$0.01-$0.11N/AN/A
5/7/2025Q1 2025
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
$0.92$0.92N/A$0.92N/A$11.87 billion
5/1/2025Q1 2025
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$4.64$3.34-$1.30$3.06$12.77 billion$12.73 billion
4/23/2025Q1 2025
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
-$0.31-$0.41-$0.10-$0.41N/AN/A
3/31/2025Q4 2024
Vivani Medical, Inc. stock logo
VANI
Vivani Medical
-$0.10-$0.11-$0.01-$0.11N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$6.000.77%N/A48.82%11 Years
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
$1.642.39%N/A48.52%N/A
Vivani Medical, Inc. stock logo
VANI
Vivani Medical
N/AN/AN/AN/AN/A
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
N/AN/AN/AN/AN/A

Latest VANI, NVO, LLY, and VKTX Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
6/23/2025
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
quarterly$1.500.78%8/15/20258/15/20259/10/2025
5/5/2025
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
quarterly$1.500.73%5/16/20255/16/20256/10/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
2.18
1.37
1.06
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
0.70
0.74
0.56
Vivani Medical, Inc. stock logo
VANI
Vivani Medical
N/A
2.40
2.40
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
N/A
44.25
44.25

Institutional Ownership

CompanyInstitutional Ownership
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
82.53%
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
11.54%
Vivani Medical, Inc. stock logo
VANI
Vivani Medical
6.78%
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
76.03%

Insider Ownership

CompanyInsider Ownership
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
0.14%
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
0.07%
Vivani Medical, Inc. stock logo
VANI
Vivani Medical
46.40%
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
4.10%
CompanyEmployeesShares OutstandingFree FloatOptionable
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
47,000947.74 million946.41 millionOptionable
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
77,3494.47 billion4.46 billionOptionable
Vivani Medical, Inc. stock logo
VANI
Vivani Medical
2059.24 million31.76 millionOptionable
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
20112.31 million107.71 millionOptionable

Recent News About These Companies

Futuristic laboratory, doctor or scientist holding glass tube, molecular and DNA structure, genetic research human biology and pharmaceutical technology, medical,science,development biological system — Photo
3 Biotech Stocks to Watch: Iovance, Neurocrine & Viking
...
VKTX Viking Therapeutics, Inc. - Seeking Alpha

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Eli Lilly and Company stock logo

Eli Lilly and Company NYSE:LLY

$776.18 -18.94 (-2.38%)
Closing price 06/27/2025 03:59 PM Eastern
Extended Trading
$777.99 +1.81 (+0.23%)
As of 05:57 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; and Chugai Pharmaceutical Co., Ltd. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.

Novo Nordisk A/S stock logo

Novo Nordisk A/S NYSE:NVO

$68.50 +0.80 (+1.18%)
Closing price 06/27/2025 03:59 PM Eastern
Extended Trading
$69.57 +1.07 (+1.57%)
As of 05:59 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with Aspen Pharmaceuticals to produce insulin products; and with Korro Bio, Inc. for the discovery and development of new genetic medicines to treat cardiometabolic diseases. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.

Vivani Medical stock logo

Vivani Medical NASDAQ:VANI

$1.32 +0.01 (+0.76%)
Closing price 06/27/2025 04:00 PM Eastern
Extended Trading
$11.40 +10.08 (+763.64%)
As of 04:00 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Vivani Medical, Inc., a clinical stage company, develops various implants that treat chronic diseases with high unmet medical need. It engages in developing a portfolio of miniature drug implants to deliver minimally fluctuating drug profiles; and implantable visual prostheses devices to deliver useful artificial vision to blind individuals. The company is headquartered in Emeryville, California.

Viking Therapeutics stock logo

Viking Therapeutics NASDAQ:VKTX

$26.52 -1.65 (-5.86%)
Closing price 06/27/2025 04:00 PM Eastern
Extended Trading
$26.80 +0.28 (+1.04%)
As of 05:52 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; VK2735, a novel dual agonist of the glucagon-like peptide, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.